ARA-290 was engineered to reproduce a small structural motif of erythropoietin's tertiary fold — the helix B region — without activating the classical erythropoietin receptor homodimer, avoiding EPO's...
ARA-290 was engineered to reproduce a small structural motif of erythropoietin's tertiary fold — the helix B region — without activating the classical erythropoietin receptor homodimer, avoiding EPO's hematopoietic (red-cell-stimulating) effect. By engaging an EPOR/CD131 heterocomplex instead, it activates anti-inflammatory and cytoprotective signaling studied for neuronal and vascular tissue repair. A blinded, placebo-controlled human trial in patients with sarcoidosis-associated small nerve fiber damage reported improved neuropathic symptoms and increased corneal nerve fiber density after 28 days of dosing.
Molecular Medicine · 2013
A blinded, placebo-controlled trial of 28 days of daily subcutaneous ARA-290 in patients with sarcoidosis-associated nerve fiber loss reported significant improvement in neuropathic symptoms and increased corneal small nerve fiber density.
View Source →Proceedings of the National Academy of Sciences · 2008
Isolated the helix B region of EPO and derived ARA-290, tissue-protective across multiple animal injury models (stroke, retinal edema, nerve trauma) while lacking erythropoietic activity.
View Source →